GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » Shiller PE Ratio

Oncternal Therapeutics (Oncternal Therapeutics) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncternal Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Oncternal Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Shiller PE Ratio Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncternal Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncternal Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Oncternal Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncternal Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Shiller PE Ratio falls into.



Oncternal Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oncternal Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Oncternal Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-3.03/129.4194*129.4194
=-3.030

Current CPI (Dec. 2023) = 129.4194.

Oncternal Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -196.000 99.695 -254.439
201406 -210.000 100.560 -270.269
201409 -84.000 100.428 -108.249
201412 -182.000 99.070 -237.755
201503 -28.000 99.621 -36.375
201506 -476.000 100.684 -611.852
201509 -56.000 100.392 -72.192
201512 -56.000 99.792 -72.626
201603 21.000 100.470 27.051
201606 -60.200 101.688 -76.617
201609 -68.600 101.861 -87.160
201612 -61.600 101.863 -78.265
201703 -54.600 102.862 -68.697
201706 -56.000 103.349 -70.126
201709 -74.200 104.136 -92.216
201712 -60.200 104.011 -74.906
201803 -86.800 105.290 -106.693
201806 -60.200 106.317 -73.281
201809 -54.600 106.507 -66.346
201812 -30.800 105.998 -37.606
201903 -33.600 107.251 -40.545
201906 -67.600 108.070 -80.955
201909 -6.400 108.329 -7.646
201912 3.400 108.420 4.059
202003 -6.200 108.902 -7.368
202006 -6.800 108.767 -8.091
202009 -4.400 109.815 -5.186
202012 -1.800 109.897 -2.120
202103 -2.400 111.754 -2.779
202106 -3.200 114.631 -3.613
202109 -3.800 115.734 -4.249
202112 -3.200 117.630 -3.521
202203 -4.000 121.301 -4.268
202206 -4.600 125.017 -4.762
202209 -4.200 125.227 -4.341
202212 -4.000 125.222 -4.134
202303 -4.000 127.348 -4.065
202306 -3.000 128.729 -3.016
202309 -3.400 129.860 -3.388
202312 -3.030 129.419 -3.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncternal Therapeutics  (NAS:ONCT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oncternal Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics (Oncternal Therapeutics) Business Description

Traded in Other Exchanges
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Executives
Gunnar F. Kaufmann officer: Chief Scientific Officer C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji officer: Chief Medical Officer 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer director, officer: President, CEO
Richard G Vincent officer: Chief Financial Officer C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan officer: Chief Technology Officer 12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen director 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
Shanghai Pharmaceuticals Holding Co., Ltd. 10 percent owner C/O ONCTEMAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceuticals (hk) Investment Ltd 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceutical (usa) Inc. 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Hazel M Aker officer: General Counsel C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Man Cho director C/O ONCTERNAL THERAPEUTICS, INC., SUITE 300, SAN DIEGO CA 92130

Oncternal Therapeutics (Oncternal Therapeutics) Headlines

From GuruFocus